The study of ANagliptin effects on Glucagon LEvels of type 2 DM patients using insulin / ANGLE study

Not Applicable

Completed

• Conditions: Type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000023414
• Lead Sponsor: Juntendo University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-08-01
• Study Completion: 2018-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1. Type 1 diabetes 2. patients with change of insulin of 4 unit and more within observation period 3. patients with change of kinds of insulin within observation period 4. patients previously treated with anagliptin 5. BMI of 30 and more 6. severe liver disease (AST or ALT 100IU/ L and more) 7. severe kidney disease or serum creatinine of 1.5mg/dl and more 8. severe heart failure or patients with attacks of myocardial infarction and angina 9. patients with stroke within 24 weeks before acquirung consent 10.patients with malignancy 11.severe diabetic complications (neuropathy, retinopathy, nephropathy) 12.severe ketosis including diabetic coma 13.anemia (Hb < 9.5g/dl) 14.enteropathy with abnormal digestion and absorption 15.patients with past history of gastrointestinal resection

Study & Design

• Study Type: Interventional
• Study Design: Not specified